Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Talampanel. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA2 known ✓ | P42262 | 2/20 | 0.80 |
| ▸ | GRIA1 known ✓ | P42261 | 1/20 | 0.80 |
| ▸ | MEN1 | O00255 | 4/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.57 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.57 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.57 |
| ▸ | BLM | P54132 | 1/20 | 0.57 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Talampanel SCHEMBL118012 | 1.00 | GRIA2 (0.80) | GRIA2GRIA1MEN1KMT2ACYP1A2 | |
| Talampanel SCHEMBL30272868 | 1.00 | GRIA2 (0.80) | GRIA2GRIA1MEN1KMT2ACYP1A2 | |
| SCHEMBL118013 | 0.92 | GRIA2 (0.80) | GRIA2GRIA1MEN1KMT2ACYP1A2 | |
| SCHEMBL14179368 | 0.89 | GRIA2 (0.73) | GRIA2GRIA1MEN1KMT2ACYP1A2 | |
| SCHEMBL4156595 | 0.89 | GRIA2 (0.67) | GRIA2GRIA1MEN1KMT2ACYP1A2 | |
| SCHEMBL4156600 | 0.89 | GRIA2 (0.67) | GRIA2GRIA1MEN1KMT2ACYP1A2 | |
| Gyki-53655 SCHEMBL8192023 | 0.89 | GRIA2 (1.00) | GRIA2GRIA1MEN1KMT2ACYP1A2 | |
| SCHEMBL8792693 | 0.89 | GRIA2 (0.75) | GRIA2GRIA1MEN1KMT2ACYP1A2 | |
| Gyki-53655 SCHEMBL351325 | 0.89 | GRIA2 (1.00) | GRIA2GRIA1MEN1KMT2ACYP1A2 | |
| SCHEMBL8792572 | 0.89 | GRIA2 (0.75) | GRIA2GRIA1MEN1KMT2ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 4588 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4370202-B1 | XENON GAS FOR USE IN THE TREATMENT OF GLIOMAS | UNIV HEIDELBERG (DE) | 2026-03-18 | — | — | EP | claimed |
| US-12577255-B2 | MDM2-based modulators of proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-03-17 | — | — | US | claimed |
| EP-4704832-A2 | BIFUNCTIONAL SMALL MOLECULES TO TARGET THE SELECTIVE DEGRADATION OF CIRCULATING PROTEINS | Biohaven Therapeutics Ltd. (VG) | 2026-03-11 | — | — | EP | claimed |
| US-20260022117-A1 | COMPOUNDS AND METHODS FOR THE ENHANCED DEGRADATION OF TARGETED PROTEINS | ARVINAS OPERATIONS INC (US) | 2026-01-22 | — | — | US | claimed |
| US-12485178-B2 | Bifunctional small molecules to target the selective degradation of circulating proteins | YALE UNIVERSITY (US) | 2025-12-02 | — | — | US | claimed |
| US-20250332274-A1 | BIFUNCTIONAL SMALL MOLECULES TO TARGET THE SELECTIVE DEGRADATION OF CIRCULATING PROTEINS | UNIV YALE (US) | 2025-10-30 | — | — | US | claimed |
| US-12364766-B2 | Bifunctional small molecules to target the selective degradation of circulating proteins | YALE UNIVERSITY (US) | 2025-07-22 | — | — | US | claimed |
| WO-2025088514-A1 | METTL3-METTL14-COMPLEX INHIBITORS FOR THE TREATMENT OF NEUROMUSCULAR DEGENERATIVE PATHOLOGIES CAUSED BY OR LINKED TO MUTATIONS IN THE FUS GENE | Università degli Studi di Roma “La Sapienza” (IT) | 2025-05-01 | — | — | WO | claimed |
| CN-119591582-A | Imide-based proteolytic modulators and related methods of use | 阿尔维纳斯运营股份有限公司 | 2025-03-11 | — | — | CN | claimed |
| US-20250032503-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | HOTH THERAPEUTICS, INC. | 2025-01-30 | — | — | US | claimed |
| US-20030073683-A1 | Administration of noncompetitive AMPA receptor antagonist for neuroprotection after traumatic brain injury | BELAYEV LUDMILA (US) | 2003-04-17 | — | — | US | claimed |
| WO-2003024458-A1 | NEUROPROTECTION AFTER TRAUMATIC BRAIN INJURY | IVAX INSTITUTE FOR DRUG RESEARCH, INC. (US) | 2003-03-27 | — | — | WO | claimed |
| JP-2002539162-A | — | — | 2002-11-19 | — | — | JP | claimed |
| EP-1161238-A1 | AMYOTROPIC LATERAL SCLEROSIS TREATMENT WITH A COMBINATION OF RILUZOLE AND AN AMPA RECEPTOR ANTAGONIST | Aventis Pharma S.A. (FR) | 2001-12-12 | — | — | EP | claimed |
| US-6329364-B1 | COMPOUND WITH CRYSTAL STRUCTURE FOR TREATMENT OF NERVOUS SYSTEM DISORDERS | ELI LILLY AND COMPANY | 2001-12-11 | — | — | US | claimed |
| US-6288057-B1 | AMPA ANTAGONIST; NERVOUS SYSTEM, BRAIN, AND PSYCHOLOGICAL DISORDERS | ELI LILLY AND COMPANY | 2001-09-11 | — | — | US | claimed |
| EP-0699676-B1 | Physical form of dihidro-2,3-benzodiazepine derivative | LILLY CO ELI (US) | 2001-02-07 | — | — | EP | claimed |
| WO-2000054772-A1 | AMYOTROPIC LATERAL SCLEROSIS TREATMENT WITH A COMBINATION OF RILUZOLE AND AN AMPA RECEPTOR ANTAGONIST | AVENTIS PHARMA S.A. (FR) | 2000-09-21 | — | — | WO | claimed |
| EP-0699678-A1 | Crystalline form of dihydro-2,3-benzodiazepine derivative | ELI LILLY AND COMPANY (US) | 1996-03-06 | — | — | EP | claimed |
| EP-0699676-A1 | Physical form of dihidro-2,3-benzodiazepine derivative | ELI LILLY AND COMPANY (US) | 1996-03-06 | — | — | EP | claimed |